The National Institute of Allergies and Infectious Diseases is leading COVID-19 clinical trial efforts through a large-scale network, called the COVID-19 Prevention Network (CoVPN). Dr. Jim Kublin, the executive director of operations program for CoVPN, shares more about this government-funded clinical trials network for COVID-19, the importance of diversity in research, and how tech is rapidly advancing medical discoveries.
HealthCast
Season 2
Episode 1
23m listen
Ensuring Participant Diversity in COVID-19 Vaccine Trials
Share
Modern technology has the power to overcome clinical trial participation challenges.
-
Dr. Jim Kublin Executive Director of Operation Programs CoVPN
Related Content
-
DOT Advisor: Federal Contracting Must Adapt to Keep Pace With AI
AI is advancing faster than federal procurement cycles, making modular contracts, AI disclosure and new pricing models increasingly critical.
11m watch -
NIST Explores AI’s Role in DevSecOps
Michael Ogata discusses NIST’s latest DevSecOps research, the growing role of AI agents and the need for new approaches to identity and authorization.
4m watch -
Coast Guard Software Yard Accelerates Secure Application Development
Coast Guard’s infrastructure official shared how the effort strengthens application development and cybersecurity.
8m watch -
Navy CTO on the Service’s AI-First Push
The service is focused on increasing speed and scale for software development and AI.
7m watch